These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 1083290

  • 1. Secondary in vitro lymphocyte-proliferative responses to syngeneic plasma cell tumors.
    Boyer PJ, Fahey JL.
    Cancer Res; 1976 Apr; 36(4):1492-8. PubMed ID: 1083290
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of lymphoid cells from normal and immune mice by syngeneic BALB/c plasma cell tumors.
    Boyer PJ, Fahey JL.
    J Immunol; 1976 Jan; 116(1):202-9. PubMed ID: 128571
    [Abstract] [Full Text] [Related]

  • 3. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA, Walker MC, Phillips-Quagliata JM.
    Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
    [Abstract] [Full Text] [Related]

  • 4. Tumor-specific immune responsiveness of the tumor-bearing host.
    Burk MW, Yu S, McKhann CF.
    Isr J Med Sci; 1976 Jan; 12(4-5):360-8. PubMed ID: 939694
    [Abstract] [Full Text] [Related]

  • 5. Fractionation of lymphocyte subpopulations which regulate mixed lymphocyte reactions.
    Rich RR, Chu L, Rich SS.
    J Immunol; 1977 Apr; 118(4):1252-8. PubMed ID: 139451
    [Abstract] [Full Text] [Related]

  • 6. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
    Norbury KC.
    Cancer Res; 1977 May 15; 37(5):1408-15. PubMed ID: 66982
    [Abstract] [Full Text] [Related]

  • 9. Functional differentiation in the genetic control of murine T lymphocyte responses to human fibrinopeptide B.
    Peterson LB, Wilner GD, Thomas DW.
    J Immunol; 1983 Feb 15; 130(2):637-43. PubMed ID: 6217245
    [Abstract] [Full Text] [Related]

  • 10. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J, Ziegler HW, Kölsch E.
    Immunology; 1981 May 15; 43(1):133-43. PubMed ID: 6265346
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Presence of suppressor cells in spleens of mice bearing a weakly immunogenic syngeneic tumor.
    Gautam SC, Deodhar SD.
    Cancer Res; 1979 Aug 15; 39(8):2945-51. PubMed ID: 313243
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differences in the responsiveness of splenic, lymph node, and peripheral blood lymphoid cells to tumor membrane extracts.
    Krueger JG, Segal RA, Moyer RC.
    Cancer Res; 1977 Jan 15; 37(1):320-2. PubMed ID: 830419
    [Abstract] [Full Text] [Related]

  • 15. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Ye QW.
    Cancer Res; 1985 Oct 15; 45(10):4932-9. PubMed ID: 4027979
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A, Altbaum I.
    J Natl Cancer Inst; 1982 Jun 15; 68(6):963-9. PubMed ID: 6953275
    [Abstract] [Full Text] [Related]

  • 18. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J, Ziegler HW, Kölsch E.
    Immunology; 1981 May 15; 43(1):145-52. PubMed ID: 6972902
    [Abstract] [Full Text] [Related]

  • 19. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr 15; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

  • 20. [Inhibition of the growth of a syngeneic weakly immunogenic tumor in mice resulting from exposures affecting T lymphocyte activity].
    Babadzhanov AS, Buntsevich AM.
    Biull Eksp Biol Med; 1983 Apr 15; 95(4):69-71. PubMed ID: 6338967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.